bioAffinity Technologies
BIAFW
4 hedge funds and large institutions have $44.2K invested in bioAffinity Technologies in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
18.68% more ownership
Funds ownership: 2.56% → 21.24% (+19%)
0% more funds holding
Funds holding: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
92% less capital inflows, than outflows
Capital inflows: $51 | Capital outflows: $636
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$51 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$636 |
BIAFW Hedge Fund Activity: Q2 2025 in Review
4 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAFW) for Q2 2025, worth a combined $44.2K — down 32% from $65.2K a quarter earlier.
Fund positioning in BIAFW was balanced in Q2 2025: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $51. The largest seller was Citadel Advisors, cutting an estimated $636.
- 4 institutional investors held bioAffinity Technologies (BIAFW) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $44.2K of bioAffinity Technologies stock for Q2 2025, down 32% quarter-over-quarter.
- 0 funds opened new bioAffinity Technologies positions in Q2 2025 and 0 closed out.
- The largest bioAffinity Technologies buyer in Q2 2025 was UBS Group, an estimated $51 added.
- The largest bioAffinity Technologies seller in Q2 2025 was Citadel Advisors, an estimated $636 sold.
Based on aggregated 13F filings for Q2 2025.